Boston Area Chapter Webinar – Coming Soon to a PC or Mobile Device Near You!

Posted by Stephanie Gaulding
On August 20, 2018

We are excited to announce that the Boston Area Chapter is expanding our educational methods to include webinars. We recognize that the Chapter’s geographically diverse membership means attendance at our evening educational programs is not always possible. We hope that by offering occasional webinars in addition to evening events, all our members will have an […]

About RNAi & Alnylam

Posted by ISPE Boston
On August 15, 2018

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel […]

Alnylam’s RNAi Therapeutic Approved by FDA

Posted by ISPE Boston
On August 15, 2018

RNAi therapeutics company Alnylam Pharmaceuticals has announced that the FDA has approved Onpattro (patisiran) lipid complex injection, a RNA interference (RNAi) therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Onpattro is the first and only FDA-approved treatment for this indication. “Alnylam was founded on the vision of harnessing the […]

“What, Me Worry?” Risk Management & Quality at the Product Show

Posted by H. Steven Kennedy
On August 13, 2018

The 2018 ISPE Boston Area Chapter Product Show is almost here! This Show has always been a great place to see the latest and greatest offerings from industry vendors and the best place to network with industry colleagues. But this year, the educational program will be the highlight of the Show with an educational agenda […]

bluebird bio and Regeneron Announce Collaboration on New Cell Therapies for Cancer

Posted by ISPE Boston
On August 9, 2018

bluebird bio and Regeneron Pharmaceuticals have announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. The collaborators will specifically leverage Regeneron’s VelociSuite® platform technologies for the discovery and characterization of fully human antibodies, as well as T cell receptors (TCRs) directed against […]

Chapter Member Anniversaries: July 2018

Posted by ISPE Boston
On August 6, 2018

Please congratulate the following members celebrating milestone anniversaries in July 2018. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Kevin Aguiar, AG Technologies LLC Oliver W. Bausch, Bausch Advanced Tech. James V. Blackwell, PhD, MBA, The Windshire Group, LLC Nicholas J. Casale, Brammer Bio LLC Patricia […]

Welcome New Members!

Posted by ISPE Boston
On August 6, 2018

We would like to introduce the members who joined ISPE in July 2018, welcome them to the Chapter and encourage them (and all of our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And […]

Summer Social Celebrates Chapter Volunteers & Sponsors

Posted by ISPE Boston
On August 2, 2018

The rain may have moved the party inside, but couldn’t drown out the fun at the Chapter’s annual Summer Social on Thursday, July 26. This year’s Summer Social was held at the Royal Sonesta in Cambridge where 100-plus attendees enjoyed beautiful views of the Charles River and city skyline. The Summer Social is an annual […]

ISPE “Women in Pharma” Kick Off Local Initiative

Posted by Katherine Leitch
On July 23, 2018

Thank you to all the energetic volunteers and attendees who helped launch the Women in Pharma (WIP) group of the ISPE Boston Area Chapter by attending our inaugural event on Thursday, June 14. Our kick off was made extra special by our gracious host, law firm McDermott Will & Emery. Their generosity allowed us to […]

Biogen Announces Positive Phase II Results for Alzheimer’s Treatment

Posted by ISPE Boston
On July 19, 2018

Biogen and its partner Eisai have announced positive topline results from the Phase II study with anti-amyloid beta protofibril antibody BAN2401 in 856 patients with early Alzheimer’s disease. The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer’s Disease Composite Score or ADCOMS, a measure of […]

Page 95 of 118«‹93 949596 97 ›»